Preventives versus treatments

Quarterly Journal of Economics

Volumn 130, Issue 3, 2015, Pages 1167-1239

  Kremer, Michael ^a   Snyder, Christopher M ^b  

^a HARVARD UNIVERSITY   (United States)

^b DARTMOUTH COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; DISEASE CONTROL; DISEASE SEVERITY; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; RISK FACTOR; VACCINE;

UNITED STATES;

EID: 84939518303     PISSN: 00335533     EISSN: 15314650     Source Type: Journal    
DOI: 10.1093/qje/qjv012     Document Type: Article

References (73)

1. Acemoglu, Daron, and Joshua Linn, ''Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,'' Quarterly Journal of Economics, 119 (2004), 1049-1090.
2. Anderson, Odin W., Patricia Collette, and Jake J. Feldman Expenditure Patterns for Personal Health Services, 1953 and 1958: Nationwide Survey (New York: Health Information Foundation, 1960).
3. Anderson, Simon P., and Régis Renault, ''Efficiency and Surplus Bounds in Cournot Competition,'' Journal of Economic Theory, 113 (2003), 253-264.
4. Barder, Owen, Michael Kremer, and Ruth Levine Making Markets for Vaccines: Ideas to Action (Washington, DC: Center for Global Development, 2005).
5. Baumol, William J., John C. Panzar, and Robert D. Willig Contestable Markets and the Theory of Industry Structure (New York: Harcourt Brace Jovanovich, 1982).
6. Bergemann, Dirk, Benjamin Brooks, and Stephen Morris, ''The Limits of Price Discrimination,'' Cowles Foundation Working Paper No. 1896RR, 2014.
7. Biehl, Andrew R., ''Durable-Goods Monopoly with Stochastic Values,'' Rand Journal of Economics, 32 (2001), 565-577.
8. Blanchflower, David G., and Andrew J. Oswald, ''Well-Being over Time in Britain and the USA,'' Journal of Public Economics, 88 (2004), 1359-1386.
9. Boulier, Bryan, ''A Shot in the Dark: Uncertainty and Vaccine Demand and Supply,'' George Washington University Working Paper, 2006.
10. Brito, Dagobert L., Eytan Sheshinski, and Michael D. Intrilligator, ''Externalities and Compulsory Vaccination,'' Journal of Public Economics, 45 (1991), 69-90.
11. Brooks, Benjamin A., ''Surveying and Selling: Belief and Surplus Extraction in Auctions,'' Princeton University Working Paper, 2013.
12. Budish, Eric, Ben N. Roin, and Heidi Williams, ''Do Fixed Patent Terms Distort Innovation? Evidence from Cancer Clinical Trials,'' NBER Working Paper No. 19430, 2013.
13. Bulow, Jeremy I., John D. Geanakoplos, and Paul D. Klemperer, ''Multimarket Oligopoly: Strategic Substitutes and Complements,'' Journal of Political Economy, 93 (1985), 488-511.
14. Centers for Disease Control and Prevention, ''Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data, United States and 6 Dependent Areas, 2010,'' HIV Surveillance Supplemental Report vol. 17, no. 3, 2012.
15. Clay, Karen B., David S. Sibley, and Padmanabhan Srinagesh, ''Ex Post vs. Ex Ante Pricing: Optional Calling Plans and Tapered Tariffs,'' Journal of Regulatory Economics, 4 (1992), 115-138.
16. Courty, Pascal, ''Ticket Pricing under Demand Uncertainty,'' Journal of Law and Economics, 46 (2003), 627-652.
17. Courty, Pascal, and Hao Li, ''Sequential Screening,'' Review of Economic Studies, 67 (2000), 697-717.
18. De Graba, Patrick, ''Buying Frenzies and Seller-Induced Excess Demand,'' Rand Journal of Economics, 26 (1995), 331-342.
19. Dunne, Eileen F., Elizabeth R. Unger, Maya Sternberg, Geraldine McQuillan, David C. Swan, Sonya S. Patel, and Lauri E. Markowitz, ''Prevalence of HPV Infection among Females in the United States,'' Journal of the American Medical Association, 297 (2007), 813-819.
20. Euerle, Brian, and Pranatharthi Haran Chandrasekar, ''Syphilis,'' in Medscape Reference, Burke A. Cunha, ed. (2012), available at http://emedicine.meds cape.com/article/229461.
21. Fabinger, Michal, and E. Glen Weyl, ''A Tractable Approach to Pass-Through Patterns with Applications to International Trade,'' SSRN Working Paper, 2014, available at http://ssrn.com/abstract=2194855.
22. Francis, Peter J., ''Dynamic Epidemiology and the Market for Vaccinations,'' Journal of Public Economics, 63 (1997), 383-406.
23. Finkelstein, Amy, ''Static and Dynamic Effect of Health Policy: Evidence from the Vaccine Industry,'' Quarterly Journal of Economics, 119 (2004), 527-564.
24. Gabaix, Xavier, ''Power Laws in Economics and Finance,'' Annual Review of Economics, 1 (2009), 255-293.
25. Garber, Alan M., Charles I. Jones, and Paul Romer, ''Insurance and Incentives for Medical Innovation,'' Forum for Health Economics & Policy, 9 (2006), 1-27.
26. GEN News Highlights, ''FDA: HIV Numbers Drove Truvada Decision,'' July 17, article no. 81247053, 2012.
27. Geoffard, Pierre-Yves, and Tomas Philipson, ''Disease Eradication: Public vs. Private Vaccination,'' American Economic Review, 87 (1997), 222-230.
28. Gersovitz, Mark, ''Births, Recoveries, Vaccinations, and Externalities,'' in Economics for an Imperfect World: Essays in Honor of Joseph E. Stiglitz, Bruce Greenwald Richard Arnott, Ravi Kanbur, and Barry Nalebuff, eds. (Cambridge, MA: MIT Press, 2003).
29. Gersovitz, Mark, and Jeffrey S. Hammer, ''The Economical Control of Infectious Diseases,'' Economic Journal, 114 (2004), 1-27.
30. Gersovitz, Mark, and Jeffrey S. Hammer, ''Tax/Subsidy Policy Toward Vector-Borne Infectious Diseases,'' Journal of Public Economics, 89 (2005), 647-674.
31. Getzen, Thomas E., ''Health Care Is an Individual Necessity and a National Luxury: Applying Multilevel Decision Models to the Analysis of Health Care Expenditures,'' Journal of Health Economics, 19 (2000), 259-270.
32. Harpavat, Sanjiv, and Sahar Nissim MicroCards: Review Cards for Medical Students (Philadelphia: Lippincott Williams & Wilkins, 2001).
33. Harris, Milton, and Artur Raviv, ''A Theory of Monopoly Pricing Schemes with Demand Uncertainty,'' American Economic Review, 71 (1981), 347-365.
34. Hartline, Jason D., and Tim Roughgarden, ''Simple Versus Optimal Mechanisms,'' Proceedings of the 10th ACM Conference on Electronic Commerce, Northwestern University, Evanston, IL, 2009.
35. Hernandez, Brenda Y., Lynne R. Wilkens, Xuemei Zhu, Pamela Thompson, Katharine McDuffie, Yurii B. Shvetsov, Lori E. Kamemoto, Jeffrey Killeen, Lily Ning, and Marc T. Goodman, ''Transmission of Human Papillomavirus in Heterosexual Couples,'' Emerging Infectious Diseases, 14 (2008), 888-894.
36. Howard, Robin S., ''Poliomyelitis and the Postpolio Syndrome,'' British Medical Journal, 330 (2005), 1314-1318.
37. Johnson, Justin P., and David P. Myatt, ''On the Simple Economics of Advertising, Marketing, and Product Design,'' American Economic Review, 96 (2006), 756-784.
38. Kaplan, Edward H., ''Modeling HIV Infectivity: Must Sex Acts Be Counted?,'' Journal of Acquired Immune Deficiency Syndromes, 3 (1990), 55-61.
39. Kessing, Sebastian G., and Robert Nuscheler, ''Monopoly Pricing with Negative Network Effects: The Case of Vaccines,'' European Economic Review, 50 (2006), 1061-1069.
40. Klein, Benjamin, Robert A. Crawford, and Armen A. Alchian, ''Vertical Integration, Appropriable Rents, and the Competitive Contracting Process,'' Journal of Law and Economics, 21 (1978), 297-326.
41. Kremer, Michael, and Rachel Glennerster Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases (Princeton, NJ: Princeton University Press, 2004).
42. Kremer, Michael, and Christopher M. Snyder, ''Why Are Drugs More Profitable Than Vaccines?,'' NBER Working Paper No. 9833, 2003.
43. Kremer, Michael, and Christopher M. Snyder, ''Worst-Case Bounds on R&D and Pricing Distortions: Theory and Disturbing Conclusions if Consumer Values Follow the World Income Distribution,'' Mimeo, Harvard University, 2015.
44. Kremer, Michael, Christopher M. Snyder, and Heidi Williams, ''Vaccines: Integrated Economic and Epidemiological Models,'' Mimeo, Harvard University, 2012.
45. Lakdawalla, Darius Noshir, and Neeraj Sood, ''Health Insurance as a Two-Part Pricing Contract,'' Journal of Public Economics, 102 (2013), 1-12.
46. Lau, Brandyn D., Brian L. Pinto, David R. Thiemann, and Christoph U. Lehmann, ''Budget Impact Analysis of Conversion from Intravenous to Oral Medication When Clinically Eligible for Oral Intake,'' Clinical Therapeutics, 33 (2011), 1792-1796.
47. Lewis, Tracy R., and David E. M. Sappington, ''Supplying Information to Facilitate Price Discrimination,'' International Economic Review, 35 (1994), 309-327.
48. Liljeros, Fredrik, Cristofer R. Edling, Luis A. Nunes Amaral, H. Eugene Stanley, and Yvonne Åberg, ''The Web of Human Sexual Contacts,'' Nature, 411 (2001), 907-908.
49. Makowski, Lewis, and Joseph M. Ostroy, ''Appropriation and Efficiency: A Revision of the First Theorem of Welfare Economics,'' American Economic Review, 85 (1995), 808-827.
50. Makowski, Lewis, and Joseph M. Ostroy, ''Perfect Competition and the Creativity of the Market,'' Journal of Economic Literature, 39 (2001), 479-535.
51. Maleug, David A., and Christopher M. Snyder, ''Bounding the Relative Profitability of Price Discrimination,'' International Journal of Industrial Organization, 24 (2006), 995-1011.
52. Mandell, Gerald L., John E. Bennett, and Raphael Dolin Principles and Practice of Infectious Diseases. 7th ed. (Philadelphia: Elsevier Churchill Livingstone, 2009).
53. McNeil, Donald G., ''Advocating Pill, U.S. Signals Shift to Prevent AIDS,'' New York Times A1, May 15, 2014.
54. Miravete, Eugenio, ''Screening Consumers through Alternative Pricing Mechanisms,'' Journal of Regulatory Economics, 9 (1996), 111-132.
55. Morbidity and Mortality Weekly Report, ''Summary of Notifiable Diseases, United States'', Centers for Disease Control and Prevention, various years, available at http://www.cdc.gov/mmwr/mmwr_nd/index.html.
56. Mueller, Steffen, Eckard Wimmer, and Jeronimo Cello, ''Poliovirus and Poliomyelitis: A Tale of Guts, Brains, and an Accidental Event,'' Virus Research, 111 (2005), 175-193.
57. National Cancer Institute, ''BRCA1 and BRCA2: Cancer Risk and Genetic Testing,'' National Cancer Institute Fact Sheet, 2009, available at http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA.
58. Newell, Richard, Adam Jaffee, and Robert N. Stavins, ''The Induced Innovation Hypothesis and Energy-Saving Technological Change,'' Quarterly Journal of Economics, 114 (1999), 907-940.
59. Oster, Emily, ''Unobservable Selection and Coefficient Stability: Theory and Evidence,'' NBER Working Paper No. 19054, 2013.
60. Ottaviani, Marco, and Andrea Prat, ''The Value of Public Information in Monopoly,'' Econometrica, 69 (2001), 1673-1683.
61. Pinkovskiy, Maxim, and Xavier Sala-i-Martin, ''Parametric Estimations of the World Distribution of Income,'' NBER Working Paper No. 15433, 2009.
62. Purcell, David W., Christopher Johnson, Amy Lansky, Joseph Prejean, Renee Stein, Paul Denning, Zaneta Gau, Hillard Weinstock, John Su, and Nicole Crepaz, ''Estimating the Population Size of Men Who Have Sex with Men in the United States to Obtain HIV and Syphillis Rates,'' Open AIDS Journal, 6 (2012), 98-107.
63. Rockstroh, J. K., S. Ewig, T. Bauer, G. Lüchters, J. Oldenburg, E. Bailly, R. Kaiser, K. E. Schneweis, H. H. Brackmann, H. J. Dengler, and T. Sauerbruch, ''Male-to-Female Transmission of HIV in a Cohort of Hemophiliacs-Frequency, Risk Factors and Effect of Sexual Counseling,'' Infection, 23 (1995), 29-32.
64. Rosenberg, Eric, ''Drug Makers Shy from Work on AIDS Vaccine,'' San Francisco ExaminerMarch 16, 1999.
65. Royce, Rachel A., Arlene Señ a, Willard Cates Jr., and Myron S. Cohen, ''Sexual Transmission of HIV,'' New England Journal of Medicine, 336 (1997), 1072-1078.
66. Snyder, Christopher M., Wills Begor, and Ernst R. Berndt, ''Economic Perspectives on the Advance Market Commitment for Pneumococcal Vaccines,'' Health Affairs, 30 (2011), 1508-1517.
67. Thomas, Patricia, ''The Economics of Vaccines,'' Harvard Medical International (HMI) WorldSeptember/October, 2002.
68. Tirole, Jean, The Theory of Industrial Organization (Cambridge, MA: MIT Press, 1988).
69. U.S. Census Bureau, ''Vintage 2007: National Tables: National Characteristics: National Sex, Race, and Hispanic Origin,'' available at http://www.census.gov/popest/data/historical/2000s/vintage_2007/index.html.
70. Weyl, E. Glen, and Michal Fabinger, ''Pass-Through as an Economic Tool: Principles of Incidence under Imperfect Competition,'' Journal of Political Economy, 121 (2013), 528-583.
71. Weyl, E. Glen, and Jean Tirole, ''Market Power Screens Willingness-to-Pay,'' Quarterly Journal of Economics, 127 (2012), 1971-2003.
72. White, Halbert, ''A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity,'' Econometrica, 48 (1980), 817-838.
73. Wilson, Peter W. F., Ralph B. D'Agostino, Daniel Levy, Albert M. Belanger, Halit Silbershatz, and William B. Kannel, ''Prediction of Coronary Heart Disease Using Risk Factor Categories,'' Circulation, 97 (1998), 1837-1847.